• The purpose of this work was to study in detail some of the factors related to the rise in portal vein pressure which accompanies sympathetic nerve stimulation. These hemodynamic factors were studied by observing the changes in hepatic artery and portal vein vascular resistances noted during controlled perfusion of the liver in vivo. Initially, the pressure-flow characteristics of the hepatic...

Pharmacological therapy of portal hypertensión can be accomplished according to different objectives. Among them, pre-primary prophylaxis aims to avoid / delay esophageal varices development while the target of primary prophylaxis is protection against first variceal bleeding. Hepatic venous pressure gradient (HVPG) measurement closely reflects portal pressure in most liver diseases whith predo...

Portal biliopathy refers to cholangiographic abnormalities which occur in patients with portal cavernoma. These changes occur as a result of pressure on bile ducts from bridging tortuous paracholedochal, epicholedochal and cholecystic veins. Bile duct ischemia may occur due prolonged venous pressure effect or result from insufficient blood supply. In addition, encasement of ducts may occur due ...

BACKGROUND Circulating miRNA-34a is increased in blood of patients with different liver diseases when compared to healthy controls. However, the origin of miRNA-34a and its possible relationship with hemodynamics and outcome in cirrhotic patients with portal hypertension is unknown. We analyzed the levels of miRNA-34a in cirrhotic patients with severe portal hypertension. METHODS We included ...

Increased hepatic vascular resistance mainly due to elevated vascular tone and to fibrosis is the primary factor in the development of portal hypertension in cirrhosis. Leptin, a hormone associated with reduction in nitric oxide bioavailability, vascular dysfunction, and liver fibrosis, is increased in patients with cirrhosis. We aimed at evaluating whether leptin influences the increased hepat...

Although the mechanisms of cirrhosis-induced portal hypertension have been studied extensively, the role of thromboxane A(2) (TXA(2)) in the development of portal hypertension has never been explicitly explored. In the present study, we sought to determine the role of TXA(2) in bile duct ligation (BDL)-induced portal hypertension in Sprague-Dawley rats. After 1 wk of BDL or sham operation, the ...

Muñoz, Javier,Agustı́nAlbillos, Marı́a Pérez-Páramo, Irma Rossi, and Melchor Alvarez-Mon. Factors mediating the hemodynamic effects of tumor necrosis factor-a in portal hypertensive rats. Am. J. Physiol. 276 (Gastrointest. Liver Physiol. 39): G687–G693, 1999.—Nitric oxide, prostacyclin, and glucagon have been implicated in promoting the hyperdynamic circulatory state of portal hypertension. Recen...

To the editor: Hepatoportal sclerosis (HS) is an idiopathic noncirrhotic intrahepatic portal hypertension characterized by splenomegaly, hypersplenism and portal hypertension. Although it is considered uncommon in developed countries there is an increasing number of cases reported which could traduce a better knowledge of this disease and a higher level of suspicion. Our objective is to report ...

Portal hypertension is the major complication of chronic liver disease and is associated with reduced survival. Pharmacological treatment is based on the premise that a sustained reduction in portal pressure will reduce the consequences of portal hypertension—that is, variceal bleeding, hepatic encephalopathy, and development of ascites. Non-selective â-blockers have proved eVective in reducing...

Portal hypertension is the major complication of chronic liver disease and is associated with reduced survival. Pharmacological treatment is based on the premise that a sustained reduction in portal pressure will reduce the consequences of portal hypertension—that is, variceal bleeding, hepatic encephalopathy, and development of ascites. Non-selective â-blockers have proved eVective in reducing...